PROFOUND MEDICAL CORP (PRN.CA) Stock News

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

Mentions: PROF

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

Mentions: PROF

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Mentions: PROF

Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th

Mentions: PROF

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the...

Mentions: PROF

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Mentions: PROF

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mentions: PROF

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of...

Mentions: PROF

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Mentions: PROF

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Mentions: PROF

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. ...

Mentions: PROF

Profound Medical Announces Proposed Public Offering of Common Shares

Mentions: PROF

Profound Medical Announces Proposed Public Offering of Common Shares

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024...

Mentions: PROF

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and...

Mentions: PROF

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Mentions: PROF

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’

TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the...

Mentions: PROF

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’

TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings

Mentions: PROF

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

Mentions: PROF

Profound Medical Announces Third Quarter 2024 Financial Results

Mentions: PROF

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code...

Mentions: PROF

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Mentions: PROF

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Mentions: PROF

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes...

Mentions: PROF

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Mentions: PROF

Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA

Mentions: PROF

Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference

TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

Mentions: PROF

Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference

Mentions: PROF

Profound Medical Announces Second Quarter 2024 Financial Results

Mentions: PROF

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Mentions: PROF

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Mentions: PROF

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Mentions: PROF

Profound Medical Annual General Meeting of Shareholders Voting Results

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting...

Mentions: PROF

Profound Medical Annual General Meeting of Shareholders Voting Results

Mentions: PROF

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan

– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – –...

Mentions: PROF